\
&
Contact us
\
&
Contact us
This was 10 months ago
Locationonline
ProgrammesThis online event brings together experts to discuss research and innovation challenges and future priorities in the areas of clean energy and mobility.
In the span of five years, since the adoption of the European Green Deal in late 2019, EU climate policy has undergone a major shift. The target is clear – climate neutrality by 2050. The steps needed to achieve this target are, despite their complexity, also relatively clear. However, the context in which the EU operates is rapidly changing. EU research and innovation (R&I) policy must therefore adapt, and quickly.
The reflection paper ‘Addressing European Research and Innovation Challenges for System Transitions in Energy and Mobility’ provides a vision, recommendations and actions for how EU R&I policy in the areas of clean energy and mobility should go about adapting to the challenges the EU now faces. This event will explore the paper’s suggestions and consider how to best to translate them from lofty ambitions to real actions.
Connect to the event via Research & Innovation Community Platform
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
